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Background: Treatment for hypertension with antihypertensive medication has been shown to reduce stroke,
cardiovascular events, and mortality in older adults, but there is concern that such treatment may not be
appropriate in frailer older adults. To investigate whether there is an interaction between effect of treatment for
hypertension and frailty in older adults, we calculated the frailty index (FI) for all available participants from the
HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives
in people with hypertension aged 80 and over, and obtained frailty adjusted estimates of the effect of treatment
with antihypertensive medication on risk of stroke, cardiovascular events, and mortality.
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Methods: Participants in HYVET were randomised 1:1 to active treatment with indapamide sustained release
1.5 mg ± perindopril 2 to 4 mg or to matching placebo. Data relating to blood pressure, comorbidities, cognitive
function, depression, and quality of life were collected at entry into the study and at subsequent follow-up visits.
The FI was calculated at entry, based on 60 potential deficits. The distribution of FI was similar to that seen in
population studies of adults aged 80 years and above (median FI, 0.17; IQR, 0.11–0.24). Cox regression was used to
assess the impact of FI at entry to the study on subsequent risk of stroke, total mortality, and cardiovascular events.
Models were stratified by region of recruitment and adjusted for sex and age at entry. Extending these models to
include a term for a possible interaction between treatment for hypertension and FI provided a formula for the
treatment effect as a function of FI. For all three models, the point estimates of the hazard ratios for the treatment
effect decreased as FI increased, although to varying degrees and with varying certainty.
Results: We found no evidence of an interaction between effect of treatment for hypertension and frailty
as measured by the FI. Both the frailer and the fitter older adults with hypertension appeared to gain from
treatment.
Conclusions: Further work to examine whether antihypertensive treatment modifies frailty as measured by the
FI should be explored.
Trial registration: ClinicalTrials.gov NCT00122811 (July 2005)
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The global population is ageing and with ageing comes
an increased prevalence of both frailty and hypertension
[1-3]. Treatment for hypertension with antihypertensive
medication has been shown to reduce stroke, cardiovas-
cular events, and mortality in older adults [4,5]. Never-
theless, the potential benefit associated with providing
treatment for hypertension must be weighed against the
potential risk of overtreatment (excessive blood pressure
lowering), polypharmacy, and the impact of side effects.
There is concern that the treatment may not be benefi-
cial in all older adults, particularly the frailest [6].
Frailty, a clinical state in which there is an increase in
an individual’s vulnerability for developing increased de-
pendency and/or mortality when exposed to a stressor
[7], has been assessed in a number of ways, varying from
evaluation of specific impairments [8] to a holistic oper-
ational definition, the Frailty Index (FI), which is quanti-
fied by counting the number of diseases, symptoms, or
similar health ‘deficits’ [3,9]. The FI theoretically ranges
from 0 to 1.0, with a higher FI indicating a higher level
of frailty, but in practice has a maximum observed value
of around 0.7 and, perhaps because it is more compre-
hensive, has been shown to be a better predictor of new
disability and mortality than the Cardiovascular Health
Study or Study of Osteoporotic Fractures scales [10]. FI
may be calculated from any data set with sufficient in-
formation related to participant deficits (the recom-
mended minimum is 30 deficits that are not saturated
within the data set) and in a number of global popula-
tion datasets has shown consistent relationships betweenageing and mortality, with higher frailty scores at older
ages and higher frailty associated with an increased risk
of death [11-16]. The deficits included in the FI do not
need to be independent of each other. Population studies
of very old adults report a mean FI of around 0.16 to 18
in those in their early 80s rising to approximately 0.20
over 90 years [13,17]. The FI is applicable at any age, but
of particular use in very elderly people, in whom frailty
levels are more widely distributed than in the general
population, i.e., ranging from the very frail to the robust
fitter older adult [17].
The HYpertension in the Very Elderly Trial (HYVET)
was a double-blind, placebo-controlled study of antihyper-
tensives in people with hypertension aged 80 and over,
which found that treatment with antihypertensives would
lead to a reduction in risk of stroke, cardiovascular events,
and total mortality [4,5]. However, participants recruited
to HYVET, in common with many clinical trials and other
studies, are likely to have been healthier than the general
very elderly hypertensive population [18]. In consequence,
the applicability of the results to the wider elderly popula-
tion has been questioned, so that uncertainty remains as
to whether treatment benefits also extend to the frailer
elderly people [6]. To investigate further, we calculated the
FI for all available HYVET study participants and obtained
frailty-adjusted estimates of the effect of antihypertensive
treatment in very elderly people.
Methods
The HYVET trial randomised participants 1:1 to active
treatment with indapamide sustained release 1.5 mg ±
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inclusion criteria for entry into HYVET have been re-
ported in full elsewhere [4]; briefly, participants were re-
quired to be hypertensive (average sitting systolic blood
pressure ≥160 mmHg), to have no condition likely to
limit life to less than a year, no diagnosis of dementia,
and no need of 24-hour nursing care. Participants gave
written informed consent and were assessed at baseline
and at 3-monthly intervals for the first year and 6-
monthly intervals thereafter until they either died, with-
drew from the study, or the trial ended. Data relating to
blood pressure, comorbidities, cognitive function, depres-
sion, and quality of life were collected at baseline and at
subsequent follow-up visits. Key relevant endpoints were
selected prior to the start of the trial and these included
incident stroke (the primary endpoint), total mortality,
and incident cardiovascular events. Data relating to trial
endpoints were collected as these occurred and the end-
points validated by an independent blinded committee.
All appropriate ethical and regulatory permissions were
obtained. Trial registration number is NCT00122811.
The FI was calculated at entry to the study and based
on 60 deficits as detailed in Additional file 1. Each deficit
was coded as either present or absent in accordance with
previous published methodology [19]. To be eligible for
inclusion in the FI, the risk of developing a deficit must in-
crease in the general population with increasing age, be
associated with varied organ systems, have negative health
associations, and be present in at least roughly 1% of the
population under study but not to be saturated in the
study data [19]. The number of deficits present was
counted for each study participant and divided by 60, the
maximum number of deficits possible in our data, to give
the FI. Information on all 60 deficits was not available for
all participants, partly because some had opted out of the
quality of life sub-study and partly because of the usual
missing data issues. Where missing data meant that the FI
calculation for a particular participant would be based
on fewer than the intended 60 possible deficits, the FI
was calculated as the number of deficits divided by the
number available for that participant. Where missing
data meant that the FI calculation for a particular par-
ticipant would be based on fewer than the recom-
mended minimum of 30 possible deficits, the FI was
not calculated but set to missing and the subject ex-
cluded from the analysis.
Cox regression [20] was used to assess the impact of FI
at entry to the study on subsequent risk of fatal and non-
fatal stroke, total mortality, and cardiovascular events
(fatal and non-fatal stroke, myocardial infarction and heart
failure). Models were stratified by region of recruitment
(Western Europe, Eastern Europe, China) to allow each to
have a different baseline hazard function (calibrate FI) and
adjusted for sex and age at entry to the study. There wasno adjustment for baseline cardiovascular disease as this
forms part of the FI. The validity of the proportional haz-
ards assumption was assessed using diagnostic plots and
Grambsch and Therneau tests [21], and the overall model
fit was assessed graphically by plotting the Nelson-Aalen
cumulative hazard function versus the Cox-Snell residuals
and comparing to a 45° reference line.
We fitted Cox regression models (stratified by region)
with terms for baseline age, sex, FI, treatment, and an
interaction between treatment and FI to obtain a formula
for the treatment effect as a function of FI [22] to illustrate
the impact of FI upon the estimate of treatment effect ob-
tained from our models. The estimates of treatment effect
from this model, and associated 95% confidence intervals
(CIs), were then presented graphically.
The relationship between baseline FI and subsequent
drop out was investigated to establish whether partici-
pants for whom the FI could not be calculated, owing to
incomplete data, differed substantially from those for
whom the FI could be calculated.
Results
Characteristics of participants
The HYVET trial randomised 3,845 participants, of
whom only the 2,656 who consented to complete an
additional quality of life questionnaire provided suffi-
cient data to allow the calculation of the FI. The baseline
characteristics of these participants are given in Table 1.
There did not appear to be any imbalance between the
treatment groups.
We also compared those for whom the FI was calculable
with those for whom it was not. There was no difference
between them in terms of age, sex, previous cardiovascu-
lar disease, or baseline sitting systolic blood pressure but
there was a difference in cognitive test score; the median
Mini-Mental State Exam (MMSE) score at entry to the
study in those in whom FI was calculable was 26.0 (Inter-
quartile range (IQR), 22–28) and in those in whom FI
was not calculable was 27.0 (IQR, 24–29) (P <0.001,
Mann–Witney test).
Frailty index (FI)
The distribution of the constituents used to calculate the
FI was similar in the two treatment groups (Additional
file 2: Table S1). The distribution of FI at entry to the
study was skewed with mean and median values 0.19
(standard deviation (SD), 0.10) and 0.17 (IQR, 0.11–
0.24), respectively, and range 0.01 to 0.63 (Figure 1).
Median FI was higher (P <0.01, Mann–Whitney rank-
sum test) for women (0.18; IQR, 0.12–0.26) compared to
men (0.15; IQR, 0.10–0.21). On average, FI scores in-
creased slowly with age (0.003 per year of age (95% CI,
0.002–0.004)). Greater FI at entry to the study was asso-
ciated with an increased risk of death (HR, 1.24 per 0.05
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Figure 1 Histogram showing the distribution of frailty index (FI) among 2,6
Table 1 Baseline characteristics of the 2,656 participants
of HYVET for whom the frailty index was calculable, by
treatment group
Placebo Active
n 1,324 1,332
Age (yrs), mean (SD) 83.4 (3.0) 83.6 (3.2)
Male 520 (39.3%) 526 (39.5%)
Female 804 (60.7%) 806 (60.5%)
Body mass index*
Underweight 39 (3%) 58 (4%)
Normal weight 587 (44%) 605 (46%)
Overweight 566 (43%) 530 (40%)
Obese 132 (10%) 138 (10%)
Sitting SBP, mean (SD) 173.1 (8.9) 173.3 (8.8)
Sitting DBP, mean (SD) 90.0 (8.9) 89.9 (8.8)
Standing SBP, mean (SD) 168.0 (11.8) 168.2 (11.9)
Standing DBP, mean (SD) 87.9 (9.9) 88.1 (9.8)
Cardiovascular disease, n (%) 177 (13.4%) 159 (11.9%)
Antihypertensive treatment prior
to entry into the trial, n (%)
830 (62.7%) 828 (62.2%)
Mini Mental State Examination,
median (IQR)
26.0 (22–28) 26.0 (22–28)
Frailty Index, median (IQR) 0.17 (0.11–0.24) 0.16 (0.11–0.24)
*Adjusted for region of recruitment.
DBP, Diastolic blood pressure; IQR, Interquartile range; SBP, Systolic blood
pressure; SD, Standard deviation.
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(HR, 1.23 per 0.05 increase in FI; 95% CI, 1.16–1.30),
and stroke (HR, 1.26 per 0.05 increase in FI; 95% CI,
1.15–1.37). Adjustment for treatment group, age, and
sex, and stratification by region of recruitment did not
alter these findings.
Effect of frailty on estimates of treatment effect from HYVET
Median follow-up was similar in the two treatment groups.
For time to death, median follow-up was 22 months (IQR,
13–34) in the placebo group compared to 23 months (IQR,
13–35) in the active treatment group; for time to cardiovas-
cular events, median follow-up was 21 months in the pla-
cebo group (IQR, 12–33) and 23 months (IQR, 13–35) in
the active treatment group; and for time to stroke, median
follow-up was 21 months (IQR, 12–34) in the placebo
group and 23 months (IQR, 13–34) in the active treatment
group. The proportionality assumption was not violated
(P values for the global Grambsch and Therneau tests of
the proportional hazards assumption for the models for
time to death, time to cardiovascular events, and time to
stroke were 0.78, 0.14, and 0.39, respectively) and overall
model fit was adequate. The estimate of treatment effect
obtained from the Cox regression models (Table 2) did not
change with adjustment for baseline FI. Treatment with an
anti-hypertensive was associated with a 36% reduction in
risk of fatal and non-fatal stroke (HR, 0.64; 95% CI, 0.42–
0.96; P = 0.03) after adjustment for baseline FI, sex, and age,
and stratification for region of recruitment. Similarly, active
treatment within HYVET significantly reduced the risk of
fatal and non-fatal cardiovascular events (HR, 0.59; 95% CI,.4 .45 .5 .55 .6 .65 .7
ex (FI)
56 participants of HYVET at entry to the study.
Table 2 Hazard ratios and associated 95% confidence intervals from Cox regression models showing the effect of
adjusting for frailty on the estimate of treatment effect in those for whom a frailty index was calculated n = 2,656
Variables included in the model Stroke (95 events) Cardiovascular events
(231 events)
Total mortality
(294 events)
Treatment group 0.65 (0.43–0.98) 0.59 (0.45–0.77) 0.83 (0.66–1.05)
Treatment group, sex, and age 0.65 (0.43–0.98) 0.59 (0.45–0.77) 0.83 (0.66–1.05)
Treatment group, sex, age, and FI
at entry to the study
0.64 (0.42–0.96) 0.59 (0.45–0.77) 0.83 (0.66–1.04)
All models stratified by region of recruitment.
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mortality between the placebo and active treatment groups
(HR, 0.83; 95% CI, 0.66–1.04). The adjusted hazard ratios
(HR) for all three endpoints were similar to those seen in
the main trial results (which were HR, 0.68; 95% CI, 0.47–
0.98 for stroke; HR, 0.66; 95% CI, 0.53–0.82 for cardiovas-
cular events, and HR, 0.79; 95% CI, 0.65–0.95 for mortality
[23]). Repeating these analyses with previous cardiovascular
disease excluded from the calculation of FI did not materi-
ally affect the results.Figure 2 Estimates of the frailty specific log hazard ratio for treatment effe
limits versus baseline frailty index, adjusted for age and sex and stratified b
non-fatal cardiovascular events. (c) Total mortality.There was no significant interaction between treatment
effect and frailty for any of the three endpoints (P values
for the interaction term in the interaction models for
stroke, cardiovascular events, and total mortality were
0.52, 0.73, and 0.61, respectively). Estimates of the log HR
for the treatment effect obtained from these interaction
models are plotted versus FI, with the associated CIs
(Figure 2) and HRs for selected values of FI (FI = 0.1, 0.2,
0.3, 0.4, 0.5, and 0.6) are reported in Table 3. For all three
models the point estimate of the HR for the treatmentct (active treatment versus placebo) and point-wise 95% confidence
y region of recruitment. (a) Fatal and non-fatal strokes. (b) Fatal and
Table 3 Estimated hazard ratios for treatment effect (active treatment versus placebo) and associated 95% confidence
intervals, by frailty index
Stroke Cardiovascular events Total mortality
Frailty index HR 95% CI HR 95% CI HR 95% CI
0.1 0.75 0.40–1.38 0.62 0.42–0.92 0.89 0.63–1.25
0.2 0.66 0.43–1.01 0.60 0.45–0.78 0.84 0.66–1.07
0.3 0.59 0.36–0.96 0.57 0.42–0.79 0.80 0.61–1.04
0.4 0.52 0.25–1.09 0.55 0.34–0.89 0.76 0.50–1.14
0.5 0.47 0.16–1.33 0.53 0.26–1.06 0.72 0.40–1.29
0.6 0.41 0.10–1.65 0.50 0.20–1.27 0.68 0.32–1.48
All models adjusted by age, sex, and interaction between treatment and frailty index, and stratified by region of recruitment.
Warwick et al. BMC Medicine  (2015) 13:78 Page 6 of 8effect decreases as FI increases, although to varying de-
grees and with varying certainty.
Association between frailty and premature withdrawal
There were 347 patients for whom baseline FI was cal-
culable but who withdrew from the study and were
therefore censored in the analysis at the date of with-
drawal. The distribution of baseline FI was not the same
for those who withdrew and those who did not withdraw
from the study (Mann–Whitney test, P <0.0001). The
median FI was 0.19 (IQR, 0.13–0.27) in those who with-
drew from the study and 0.16 (IQR, 0.11–0.24) in those
who did not withdraw. The withdrawal rate in the least
frail category (FI ≤0.10) was 9% compared to 17% in the
frailest category (FI ≥0.35) and there was no difference in
withdrawal rate between the treatment groups (14.38%
placebo group vs. 14.90% active treatment group). Within
the most frail category (FI ≥0.35), the withdrawal rate was
21% in the active treatment group (n = 99) compared to
14% (n = 94) in the placebo group, but this was not signifi-
cant (P = 0.18, χ2 test).
Discussion
Frailty as measured by the FI was a strong predictor of
stroke, total mortality, and cardiovascular events in the
HYVET trial, which is in agreement with multiple ana-
lyses from observational datasets [8-13]. We found no
evidence of an interaction between baseline FI and treat-
ment with antihypertensives on risk of stroke, death
from all causes, or cardiovascular events in very elderly
people. Furthermore, the burden of frailty amongst
HYVET participants at baseline was similar to that seen
in population studies [13-17].
Overall this suggests both that the HYVET population
is more representative in terms of frailty than may have
been supposed, and that benefits associated with blood
pressure lowering treatment are accrued in both frailer
and fitter older adults. These results would imply that
frailty alone should not be used as a criteria for determin-
ing whether or not the treatment of an individual aged 80
and over with an antihypertensive to lower blood pressureto a goal of <150/80 mmHg is justified. Nevertheless, fur-
ther work is required to fully characterize the benefit risk
balance in this age group, with particular attention paid to
the impact of any treatment adverse effects and/or a diag-
nosis of dementia, especially as there is epidemiological
evidence to suggest that high blood pressure may not be
harmful, and may even be beneficial, in the very elderly
who are frail or have a functional disability [24-27]. In
general, as the degree of frailty increases, so does the
chance of functional impairment [28,29] or mobility im-
pairment [30]. Furthermore, as the associations between
risk factors and adverse outcomes may differ at extreme
age and in frailty subgroups, and be dependent on risk fac-
tor change over time, a more nuanced approach to the in-
terpretation of results may be required.
However, our results must be interpreted with caution.
The number of items (at least 30) required to complete an
FI meant that, of the 3,845 participants randomized, only
the 2,656 (69%) who consented to complete an additional
quality of life questionnaire had sufficient data. Neverthe-
less, it is reassuring that those for whom an FI was not cal-
culable differed chiefly only in relation to cognition,
scoring on average one point higher on the MMSE at
entry, statistically but not clinically different. It is also pos-
sible that treatment with an anti-hypertensive may have
affected participant withdrawals differentially, leading to
bias in our estimate of the treatment effect. However, we
found no difference in withdrawal rate between the treat-
ment groups (14.38% placebo group vs. 14.90% active
treatment group) and even amongst the frailest partici-
pants (FI ≥0.35) the withdrawal rate was only 17% overall.
Although only 2,656 participants were available from the
HYVET trial for these analyses these data still represent a
significant number of older adults.
One must also be careful not to over interpret the re-
sults from the interaction models presented in Table 3
and Figure 2. Although the estimate of the log HR de-
creases as FI increases for all three endpoints, the inter-
action term in the respective models were not significant
(overall the relationship between frailty and treatment
effect was not strong). Furthermore, the wider CIs in the
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data lies in the region FI <0.1 and FI >0.4 (Figure 2).
This analysis has some strengths. In particular, the use
of data from a double-blind, placebo-controlled clinical
trial also allows exploration of this by randomised group
providing a more robust finding that would be possible
from observational data alone. The similarity of the FI at
baseline with large observational datasets supports the po-
tential applicability of the results. As far as the authors
know, this is the first time the FI has been used in analys-
ing the results of a clinical trial, particularly a hypertensive
very elderly group. Although only 69% of the randomized
patients were included, this still constitutes a significant
number within the literature base for this age group.
Conclusions
Our analyses show that in the HYVET study participants
there was no evidence of an interaction between treatment
effect and frailty. Both the frailer and the fitter older adults
with hypertension appeared to gain from treatment. Fur-
ther work in is needed to confirm these findings in other
similar datasets and to explore whether antihypertensive
treatment modifies frailty as measured by the FI. Add-
itionally, examining this more holistically, looking at im-
pact of treatment over time, would be of additional benefit
and is motivating further research by our group.
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